Chris Huntsman is an associate in Goodwin’s Business Law department and a member of its nationally recognized Life Sciences group. Chris represents public and private life science companies through every stage of the corporate life cycle, including startup and formation, venture capital financings, public offerings, mergers and acquisitions and general corporate representation. He joined Goodwin in 2018.
Representative Matters
Chris’ recent client representations include the following:
- Bicara Therapeutics in its $362 million initial public offering
- AlloVir in:
- its $75 million follow-on offering
- its $126.6 million registered direct offering
- Fulcrum Therapeutics in its $125 million follow-on offering
- Ikena Oncology in:
- its $133.6 million initial public offering
- its $100 million “at-the-market” offering
- its $40 million underwritten offering
- Blueprint Medicines in:
- its $250 million “at-the-market” offering
- its $300 million “at-the-market” offering
- iTeos Therapeutics in its $201 million initial public offering
- Xeris Pharmaceuticals in:
- its $85 mill and $37 million follow-on offering
- its $95 million concurrent equity and convertible notes offerings;
- multiple registered direct offerings
- its convertible notes exchange
- Orchard Therapeutics in its:
- $225.5 million initial public offering and initial U.S. listing
- its $128.3 million follow-on offering
- its $150 million PIPE
- Atlas Ventures and Access Biotechnology in their investment in GRO Biosciences $60 million Series B financing
- Ikena Oncology in its $120 million Series B financing
- iTeos Therapeutics in its $125 million Series B2 financing
- Gemini Therapeutics in its $50 million Series B financing
- Nimbus Therapeutics in the sale of its allosteric TYK2 inhibitor program to Takeda for $4 billion upfront and up to $6 billion in total
- Blueprint Medicines in:
- its acquisition of Lengo Therapeutics for $250 million upfront and up to $465 million in total
- its strategic financing collaboration with Sixth Street Partners for up to $910 million
- AnaptysBio in its sale to DRI Capital of royalties on sales of Zejula for $35 million upfront and a $10 million milestone payment
- Pardes Biosciences in its business combination agreement with FS Development Corp. II
- Xeris Pharmaceuticals in its cross-border acquisition of Strongbridge Biopharma
- Gemini Therapeutics in its business combination agreement with FS Development Corp
- Acquia in:
- its sale to Vista Equity Partners
- its acquisition of Cohesion Web Technologies Limited
- its acquisition of Mautic
Professional Activities
Professional Experience
Prior to joining Goodwin, Chris was an Enforcement Attorney with the Massachusetts Securities Division. While with the Division, Chris was the Co-Chair of the Division’s Initial Coin Offering (“ICO”) Task Force. Chris was a member of a small team of Division Enforcement Attorneys that filed the first state complaint against an ongoing ICO.
While in law school, Chris worked as a law clerk for State Street Bank & Trust and Alere, Inc. Additionally, Chris worked as a legal intern with the United States Attorney’s Office for the District of Massachusetts, as well as with the Honorable Frank J. Bailey of the United States Bankruptcy Court for the District of Massachusetts. Chris served as an Articles Editor on the Northeastern University Law Review.
Credentials
Education
JD2016
Northeastern University School of Law
BSMLegal Studies in Business, Marketing2011
Tulane University
Admissions
Bars
- Massachusetts